A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age - MI-CP206

Exclusion Criteria

• - Acute illness or evidence of significant active infection at randomization
• - Fever greater than or equal to 100.4 degrees F (38°C) at randomization
• - History of asthma
• - Any drug therapy from 15 days prior to randomization or expected drug therapy through 30 days post dose with the exception of contraceptives;
• topical corticosteroids or antifungals for uncomplicated dermatitis;
• chronic medications (including those taken on an as-needed basis) that were well tolerated and were not initiated and/or did not have a dosage change within 90 days of randomization
• - Previous medical history or evidence of an intercurrent illness that may have compromised the safety of the participant in the study
• - Current or expected receipt of immunosuppressive medications (inhaled and topical corticosteroids and topical calcineurin inhibitors were permitted) within a 30-day window around the dose
• - Receipt of immunoglobulin or blood products within 90 days before randomization into the study or expected receipt during study participation
• - Receipt of any investigational drug therapy within 30 days prior to randomization or planned receipt of any investigational drug therapy through 30 days after dosing of investigational product (use of licensed agents for indications not listed in the package insert were permitted)
• - Receipt of any nonstudy vaccine within 30 days prior to randomization or planned receipt of nonstudy vaccine through 30 days after dosing
• - Receipt of any influenza vaccine (investigational or licensed) in 2009 prior to randomization or anticipated receipt prior to the collection of the post-dose immunogenicity blood sample for this study
• - Any known immunosuppressive condition or immune deficiency disease including known or suspected infection with human immunodeficiency virus (HIV)
• - History of allergic disease or reactions likely to be exacerbated by any component of Q/LAIV-BFS including allergy to eggs, egg proteins, gentamicin, or gelatin, or serious, life threatening, or severe reactions to previous influenza vaccinations
• - History of Guillain-Barré syndrome
• - Use of antiviral agents with activity against influenza virus (including amantadine, rimantadine, oseltamivir and zanamivir) within 30 days prior to receipt of investigational product or anticipated use within 30 days after receipt of investigational product
• - Known or suspected mitochondrial encephalomyopathy
• -Pregnant or lactating female
• - Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of participant safety or study results
• - Participant, legal guardian, or immediate family member of participant who was an employee of the clinical study site or who was otherwise involved with the conduct of the study